^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IMCnyeso

i
Other names: IMCnyeso, GSK01, GSK3537142, NY-ESO-1 ImmTAC , 3537142, bispecific NY-ESO-1- and LAGE-1A-specific TCR/anti-CD3, HLA- A*0201-restricted NY-ESO-1- and LAGE-1A-specific soluble TCR/anti-CD3 bispecific molecule, NY-ESO-1, GSK1, GSK-01–NY-ESO
Associations
Trials
Company:
GSK, Immunocore
Drug class:
Immunomodulator
Related drugs:
Associations
Trials
12ms
Modulation of TRPV4-mediated TNF-α expression in Müller glia and subsequent RGC apoptosis by statins. (PubMed, Exp Eye Res)
Cells were pretreated with simvastatin or lovastatin before GSK101...Herein, we showed that statins can modulate gliosis and TNF-α expression in Müller cells, protecting RGCs. These data further support the neuroprotective effect of statins, promoting them as a potential treatment for glaucoma.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • TRPV4 (Transient Receptor Potential Cation Channel Subfamily V Member 4)
|
IMCnyeso • lovastatin
almost3years
Enrollment change
|
CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
|
HLA-A*02:01
|
IMCnyeso
over3years
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (clinicaltrials.gov)
P1/2, N=63, Terminated, Immunocore Ltd | Active, not recruiting --> Terminated; Strategic decision to stop development and not based on any safety concerns
Clinical • Trial termination
|
CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
|
HLA-A*02:01
|
IMCnyeso
over3years
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (clinicaltrials.gov)
P1/2, N=63, Active, not recruiting, Immunocore Ltd | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
|
IMCnyeso